Loading stock data…
KZIA
$13.39-0.25 (-1.83%)
Market ClosedLast close May 1
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Kazia Therapeutics Limited in the Healthcare sector is trading at $13.39. The stock is currently 23% below its 52-week high of $17.40, remaining 63.9% above its 200-day moving average. Technical signals show overbought RSI of 80 and bullish MACD crossover, explaining why KZIA maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 80) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$13.39
Potential Upside
5%
Whystock Fair Value$14.06
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$133.57M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.62
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-53.04%
Volume
Today's trading volume
246,109
Recent News
How Kazia Therapeutics Ltd (KZIA) Is Strengthening Its Team and Platform
Kazia Therapeutics Ltd (NASDAQ:KZIA) is among the best Australian stocks to buy in 2026. Kazia Therapeutics Ltd (NASDAQ:KZIA) recently strengthened its team and expanded its platform as it works to address unmet needs in the cancer treatment space. On April 15, the company announced the appointment of Sudha Rao as its chief scientific officer. Rao […]
US Equity Futures Mixed Pre-Bell Monday Despite Oil Sector Surge
Investors revved up oil and oil services shares premarket Monday, but US equity futures were mixed f
Traders Await Nvidia Earnings, Fed Minutes, Driving Narrow Premarket Gains for US Equity Futures
US equity futures posted narrow gains ahead of Wednesday's opening bell as traders looked ahead to N
Kazia Reports Over 50% Cancer Cell Reduction In Early Data From Breast Cancer Trial, Stock Jumps
Kazia Therapeutics (NASDAQ:KZIA) on Wednesday reported preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxalisib, Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab), and standard chemotherapy after completing Cycle 1 (21 days) of dosing. The patient, a 61-year-old woman with metastatic triple-negative breast cancer localized to the left upper lobe of the lung, has shown highly encouraging preliminary results at 21 days, with a >50% reduction
Kazia Therapeutics First Half 2025 Earnings: AU$12.29 loss per share (vs AU$18.40 loss in 1H 2024)
Kazia Therapeutics ( NASDAQ:KZIA ) First Half 2025 Results Key Financial Results Revenue: AU$22.3k (up by AU$22.3k from...